
Vijaya Diagnostic (VIJAYA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.9B
Gross Profit
1.7B
88.61%
Operating Income
526.4M
27.99%
Net Income
385.9M
20.52%
EPS (Diluted)
₹3.75
Balance Sheet Metrics
Total Assets
12.7B
Total Liabilities
4.7B
Shareholders Equity
8.0B
Debt to Equity
0.59
Cash Flow Metrics
Operating Cash Flow
282.3M
Free Cash Flow
-321.8M
Revenue & Profitability Trend
Vijaya Diagnostic Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 6.8B | 5.5B | 4.6B | 4.6B | 3.8B |
Cost of Goods Sold | 847.6M | 654.4M | 588.8M | 715.0M | 570.9M |
Gross Profit | 6.0B | 4.8B | 4.0B | 3.9B | 3.2B |
Gross Margin % | 87.6% | 88.0% | 87.2% | 84.5% | 84.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 988.8M | 781.7M | 669.0M | 517.3M |
Other Operating Expenses | 2.1B | 711.4M | 605.2M | 484.6M | 432.6M |
Total Operating Expenses | 2.1B | 1.7B | 1.4B | 1.2B | 949.9M |
Operating Income | 2.0B | 1.6B | 1.2B | 1.5B | 1.2B |
Operating Margin % | 29.7% | 29.9% | 26.2% | 32.7% | 30.8% |
Non-Operating Items | |||||
Interest Income | - | 59.7M | 82.8M | 98.0M | 96.0M |
Interest Expense | 267.4M | 219.6M | 194.2M | 152.1M | 135.1M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.9B | 1.6B | 1.1B | 1.5B | 1.1B |
Income Tax | 493.7M | 390.4M | 283.0M | 367.2M | 270.0M |
Effective Tax Rate % | 25.6% | 24.6% | 24.9% | 24.9% | 24.1% |
Net Income | 1.4B | 1.2B | 852.1M | 1.1B | 851.3M |
Net Margin % | 21.1% | 21.8% | 18.6% | 23.9% | 22.6% |
Key Metrics | |||||
EBITDA | 2.9B | 2.3B | 1.9B | 2.1B | 1.8B |
EPS (Basic) | ₹13.95 | ₹11.62 | ₹8.29 | ₹10.76 | ₹8.28 |
EPS (Diluted) | ₹13.92 | ₹11.59 | ₹8.26 | ₹10.69 | ₹8.28 |
Basic Shares Outstanding | 102562939 | 102221031 | 102041263 | 101965926 | 101965926 |
Diluted Shares Outstanding | 102562939 | 102221031 | 102041263 | 101965926 | 101965926 |
Income Statement Trend
Vijaya Diagnostic Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 128.0M | 222.4M | 241.7M | 110.5M | 66.9M |
Short-term Investments | 2.7B | 1.6B | 2.3B | 2.1B | 2.1B |
Accounts Receivable | 147.6M | 162.4M | 94.9M | 97.7M | 67.0M |
Inventory | 49.3M | 51.8M | 20.5M | 42.8M | 26.4M |
Other Current Assets | 62.5M | 45.7M | 50.9M | 41.0M | -400.0K |
Total Current Assets | 3.1B | 2.1B | 2.8B | 2.7B | 2.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 7.2B | 258.9M | 211.4M | 145.8M | 106.6M |
Goodwill | 2.6B | 2.6B | 135.0M | 121.0M | 125.1M |
Intangible Assets | 218.9M | 211.8M | 28.3M | 14.3M | 18.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 136.2M | 61.9M | 86.2M | 222.8M | -100 |
Total Non-Current Assets | 9.7B | 7.7B | 5.8B | 4.4B | 3.0B |
Total Assets | 12.7B | 9.8B | 8.5B | 7.1B | 5.4B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 331.3M | 329.5M | 277.1M | 216.4M | 221.6M |
Short-term Debt | 231.6M | 201.3M | 145.3M | 132.0M | 113.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 44.3M | 35.3M | 31.9M | 36.1M | 30.2M |
Total Current Liabilities | 1.6B | 728.7M | 661.7M | 661.2M | 442.9M |
Non-Current Liabilities | |||||
Long-term Debt | 3.0B | 2.4B | 2.3B | 1.7B | 1.3B |
Deferred Tax Liabilities | 52.8M | - | - | - | - |
Other Non-Current Liabilities | 3.0M | 3.4M | 4.6M | 1.2M | 2.2M |
Total Non-Current Liabilities | 3.1B | 2.5B | 2.4B | 1.8B | 1.4B |
Total Liabilities | 4.7B | 3.2B | 3.1B | 2.4B | 1.8B |
Equity | |||||
Common Stock | 102.6M | 102.3M | 102.1M | 102.0M | 45.3M |
Retained Earnings | - | 5.9B | 4.8B | 4.1B | 3.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.0B | 6.6B | 5.5B | 4.7B | 3.6B |
Key Metrics | |||||
Total Debt | 3.2B | 2.6B | 2.5B | 1.8B | 1.4B |
Working Capital | 1.4B | 1.4B | 2.1B | 2.0B | 1.9B |
Balance Sheet Composition
Vijaya Diagnostic Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.9B | 1.6B | 1.1B | 1.5B | 1.1B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 15.9M | 9.3M | 7.2M | 11.4M | 2.0M |
Working Capital Changes | -91.5M | -58.5M | 10.2M | -81.2M | -47.8M |
Operating Cash Flow | 2.0B | 1.7B | 1.3B | 1.5B | 1.1B |
Investing Activities | |||||
Capital Expenditures | -926.1M | -846.3M | -1.2B | -1.2B | -312.3M |
Acquisitions | 0 | -1.5B | 0 | -17.0M | 0 |
Investment Purchases | -1.5B | - | -800.4M | -247.7M | -1.3B |
Investment Sales | 585.4M | 824.7M | 886.9M | 120.8M | 275.3M |
Investing Cash Flow | -1.9B | -1.5B | -1.2B | -1.4B | -1.3B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -102.6M | -102.3M | -102.1M | - | - |
Debt Issuance | - | - | - | - | 0 |
Debt Repayment | - | 0 | -6.3M | -38.4M | -282.6M |
Financing Cash Flow | -61.6M | -71.8M | -103.2M | -44.0M | -283.7M |
Free Cash Flow | 1.3B | 953.4M | 397.7M | 356.5M | 975.1M |
Net Change in Cash | 127.6M | 128.6M | -7.7M | 58.8M | -529.5M |
Cash Flow Trend
Vijaya Diagnostic Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
71.92
Forward P/E
52.93
Price to Book
13.58
Price to Sales
15.19
PEG Ratio
52.93
Profitability Ratios
Profit Margin
21.04%
Operating Margin
27.99%
Return on Equity
17.90%
Return on Assets
11.23%
Financial Health
Current Ratio
1.89
Debt to Equity
39.99
Beta
-0.10
Per Share Data
EPS (TTM)
₹14.66
Book Value per Share
₹77.65
Revenue per Share
₹69.62
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
vijaya | 108.3B | 71.92 | 13.58 | 17.90% | 21.04% | 39.99 |
Syngene | 270.4B | 52.09 | 5.57 | 10.50% | 13.61% | 12.23 |
Dr. Lal PathLabs | 266.2B | 51.82 | 12.24 | 22.08% | 20.29% | 7.14 |
Sai Life Sciences | 172.9B | 96.16 | 8.10 | 7.99% | 12.76% | 16.56 |
Metropolis | 104.2B | 68.04 | 7.82 | 11.96% | 10.89% | 15.30 |
Thyrocare | 70.9B | 66.67 | 12.96 | 16.73% | 14.69% | 4.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.